A citation-based method for searching scientific literature

Annalisa Lonetti, Alessandra Cappellini, Alice Bertaina, Franco Locatelli, Andrea Pession, Francesca Buontempo, Camilla Evangelisti, Cecilia Evangelisti, Ester Orsini, Laura Zambonin, Luca Maria Neri, Alberto Maria Martelli, Francesca Chiarini. J Hematol Oncol 2016
Times Cited: 29







List of co-cited articles
187 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Annalisa Lonetti, Alessandra Cappellini, Antonino Maria Spartà, Francesca Chiarini, Francesca Buontempo, Camilla Evangelisti, Cecilia Evangelisti, Ester Orsini, James A McCubrey, Alberto Maria Martelli. Oncotarget 2015
30
24

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.
Ana Silva, J Andrés Yunes, Bruno A Cardoso, Leila R Martins, Patrícia Y Jotta, Miguel Abecasis, Alexandre E Nowill, Nick R Leslie, Angelo A Cardoso, Joao T Barata. J Clin Invest 2008
332
20

JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
C Delgado-Martin, L K Meyer, B J Huang, K A Shimano, M S Zinter, J V Nguyen, G A Smith, J Taunton, S S Winter, J R Roderick,[...]. Leukemia 2017
73
20

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
L M Neri, A Cani, A M Martelli, C Simioni, C Junghanss, G Tabellini, F Ricci, P L Tazzari, P Pagliaro, J A McCubrey,[...]. Leukemia 2014
85
17

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Francesca Chiarini, Federica Falà, Pier Luigi Tazzari, Francesca Ricci, Annalisa Astolfi, Andrea Pession, Pasqualepaolo Pagliaro, James A McCubrey, Alberto M Martelli. Cancer Res 2009
96
17

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Alice Cani, Carolina Simioni, Alberto M Martelli, Giorgio Zauli, Giovanna Tabellini, Simona Ultimo, James A McCubrey, Silvano Capitani, Luca M Neri. Oncotarget 2015
23
21

Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
A Lonetti, I L Antunes, F Chiarini, E Orsini, F Buontempo, F Ricci, P L Tazzari, P Pagliaro, F Melchionda, A Pession,[...]. Leukemia 2014
53
17

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
C Simioni, L M Neri, G Tabellini, F Ricci, D Bressanin, F Chiarini, C Evangelisti, A Cani, P L Tazzari, F Melchionda,[...]. Leukemia 2012
62
17

The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Mohiuddin Gazi, Sausan A Moharram, Alissa Marhäll, Julhash U Kazi. Cancer Lett 2017
30
17

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Shannon L Maude, Sibasish Dolai, Cristina Delgado-Martin, Tiffaney Vincent, Alissa Robbins, Arthavan Selvanathan, Theresa Ryan, Junior Hall, Andrew C Wood, Sarah K Tasian,[...]. Blood 2015
148
17

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Sofie Peirs, Filip Matthijssens, Steven Goossens, Inge Van de Walle, Katia Ruggero, Charles E de Bock, Sandrine Degryse, Kirsten Canté-Barrett, Delphine Briot, Emmanuelle Clappier,[...]. Blood 2014
149
17

The molecular basis of T cell acute lymphoblastic leukemia.
Pieter Van Vlierberghe, Adolfo Ferrando. J Clin Invest 2012
323
13

Modern therapy of acute lymphoblastic leukemia.
Renato Bassan, Dieter Hoelzer. J Clin Oncol 2011
329
13

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Cecilia Evangelisti, Alessandra Cappellini, Mariana Oliveira, Rita Fragoso, João T Barata, Alice Bertaina, Franco Locatelli, Carolina Simioni, Luca M Neri, Francesca Chiarini,[...]. J Cell Physiol 2018
21
19

Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.
Deborah Bongiovanni, Valentina Saccomani, Erich Piovan. Int J Mol Sci 2017
43
13

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Julie Irving, Elizabeth Matheson, Lynne Minto, Helen Blair, Marian Case, Christina Halsey, Isabella Swidenbank, Frida Ponthan, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz,[...]. Blood 2014
160
13

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Jinghui Zhang, Li Ding, Linda Holmfeldt, Gang Wu, Sue L Heatley, Debbie Payne-Turner, John Easton, Xiang Chen, Jianmin Wang, Michael Rusch,[...]. Nature 2012
13

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.
Adolfo A Ferrando, Donna S Neuberg, Jane Staunton, Mignon L Loh, Christine Huard, Susana C Raimondi, Fred G Behm, Ching Hon Pui, James R Downing, D Gary Gilliland,[...]. Cancer Cell 2002
795
13

Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
Amélie Trinquand, Aline Tanguy-Schmidt, Raouf Ben Abdelali, Jérôme Lambert, Kheira Beldjord, Etienne Lengliné, Noémie De Gunzburg, Dominique Payet-Bornet, Ludovic Lhermitte, Hossein Mossafa,[...]. J Clin Oncol 2013
156
13

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Triona Ni Chonghaile, Justine E Roderick, Cian Glenfield, Jeremy Ryan, Stephen E Sallan, Lewis B Silverman, Mignon L Loh, Stephen P Hunger, Brent Wood, Daniel J DeAngelo,[...]. Cancer Discov 2014
142
13

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
Yu Liu, John Easton, Ying Shao, Jamie Maciaszek, Zhaoming Wang, Mark R Wilkinson, Kelly McCastlain, Michael Edmonson, Stanley B Pounds, Lei Shi,[...]. Nat Genet 2017
443
13

Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.
P Richter-Pechańska, J B Kunz, J Hof, M Zimmermann, T Rausch, O R Bandapalli, E Orlova, G Scapinello, J C Sagi, M Stanulla,[...]. Blood Cancer J 2017
56
13

Novel biological insights in T-cell acute lymphoblastic leukemia.
Kaat Durinck, Steven Goossens, Sofie Peirs, Annelynn Wallaert, Wouter Van Loocke, Filip Matthijssens, Tim Pieters, Gloria Milani, Tim Lammens, Pieter Rondou,[...]. Exp Hematol 2015
75
13

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.
Elaine Coustan-Smith, Charles G Mullighan, Mihaela Onciu, Frederick G Behm, Susana C Raimondi, Deqing Pei, Cheng Cheng, Xiaoping Su, Jeffrey E Rubnitz, Giuseppe Basso,[...]. Lancet Oncol 2009
575
13

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
Teresa Palomero, Maria Luisa Sulis, Maria Cortina, Pedro J Real, Kelly Barnes, Maria Ciofani, Esther Caparros, Jean Buteau, Kristy Brown, Sherrie L Perkins,[...]. Nat Med 2007
672
10


Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.
Francesca Chiarini, Annalisa Lonetti, Camilla Evangelisti, Francesca Buontempo, Ester Orsini, Cecilia Evangelisti, Alessandra Cappellini, Luca M Neri, James A McCubrey, Alberto M Martelli. Biochim Biophys Acta 2016
86
10

The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia.
Alejandro Gutierrez, Alex Kentsis, Takaomi Sanda, Linda Holmfeldt, Shann-Ching Chen, Jianhua Zhang, Alexei Protopopov, Lynda Chin, Suzanne E Dahlberg, Donna S Neuberg,[...]. Blood 2011
131
10

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Simona Ultimo, Carolina Simioni, Alberto M Martelli, Giorgio Zauli, Camilla Evangelisti, Claudio Celeghini, James A McCubrey, Giorgia Marisi, Paola Ulivi, Silvano Capitani,[...]. Oncotarget 2017
10
30

PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia.
André Bortolini Silveira, Angelo Brunelli Albertoni Laranjeira, Gisele Olinto Libanio Rodrigues, Paulo César Leal, Bruno António Cardoso, João Taborda Barata, Rosendo Augusto Yunes, Nilson Ivo Tonin Zanchin, Sílvia Regina Brandalise, José Andrés Yunes. Oncotarget 2015
22
13

Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy.
R E Mudry, J E Fortney, T York, B M Hall, L F Gibson. Blood 2000
159
10

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.
Lauren M Thorpe, Haluk Yuzugullu, Jean J Zhao. Nat Rev Cancer 2015
795
10

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Brittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Jorge Cortes, Gautam Borthakur, LaKiesha DeBose, Zhihong Zeng, Heather Schneider, Naveen Pemmaraju,[...]. Am J Hematol 2017
32
10

The genetics and molecular biology of T-ALL.
Tiziana Girardi, Carmen Vicente, Jan Cools, Kim De Keersmaecker. Blood 2017
162
10

Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Yana Pikman, Gabriela Alexe, Giovanni Roti, Amy Saur Conway, Andrew Furman, Emily S Lee, Andrew E Place, Sunkyu Kim, Chitra Saran, Rebecca Modiste,[...]. Clin Cancer Res 2017
68
10

Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.
Koichi Oshima, Hossein Khiabanian, Ana C da Silva-Almeida, Gannie Tzoneva, Francesco Abate, Alberto Ambesi-Impiombato, Marta Sanchez-Martin, Zachary Carpenter, Alex Penson, Arianne Perez-Garcia,[...]. Proc Natl Acad Sci U S A 2016
117
10

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
Renate De Smedt, Sofie Peirs, Julie Morscio, Filip Matthijssens, Juliette Roels, Lindy Reunes, Beatrice Lintermans, Steven Goossens, Tim Lammens, Nadine Van Roy,[...]. Haematologica 2019
15
20

STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.
Daniel Ribeiro, Alice Melão, Ruben van Boxtel, Cristina I Santos, Ana Silva, Milene C Silva, Bruno A Cardoso, Paul J Coffer, João T Barata. Blood Adv 2018
34
10

Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.
Irene Homminga, Rob Pieters, Anton W Langerak, Johan J de Rooi, Andrew Stubbs, Monique Verstegen, Maartje Vuerhard, Jessica Buijs-Gladdines, Clarissa Kooi, Petra Klous,[...]. Cancer Cell 2011
256
10

Loss-of-function mutations of Dynamin 2 promote T-ALL by enhancing IL-7 signalling.
C S Tremblay, F C Brown, M Collett, J Saw, S K Chiu, S E Sonderegger, S E Lucas, R Alserihi, N Chau, M L Toribio,[...]. Leukemia 2016
44
10

Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Sathish K R Padi, Libia A Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H Song, Jon C Aster, Xue-Zhong Yu, Shikhar Mehrotra, Andrew S Kraft. Oncotarget 2017
28
10

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Priscila P Zenatti, Daniel Ribeiro, Wenqing Li, Linda Zuurbier, Milene C Silva, Maddalena Paganin, Julia Tritapoe, Julie A Hixon, André B Silveira, Bruno A Cardoso,[...]. Nat Genet 2011
274
10

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Yunlei Li, Jessica G C A M Buijs-Gladdines, Kirsten Canté-Barrett, Andrew P Stubbs, Eric M Vroegindeweij, Willem K Smits, Ronald van Marion, Winand N M Dinjens, Martin Horstmann, Roland P Kuiper,[...]. PLoS Med 2016
73
10

Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.
Bing Chen, Lu Jiang, Meng-Ling Zhong, Jian-Feng Li, Ben-Shang Li, Li-Jun Peng, Yu-Ting Dai, Bo-Wen Cui, Tian-Qi Yan, Wei-Na Zhang,[...]. Proc Natl Acad Sci U S A 2018
73
10

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
S Degryse, C E de Bock, S Demeyer, I Govaerts, S Bornschein, D Verbeke, K Jacobs, S Binos, D A Skerrett-Byrne, H C Murray,[...]. Leukemia 2018
52
10

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
K Canté-Barrett, J A P Spijkers-Hagelstein, J G C A M Buijs-Gladdines, J C M Uitdehaag, W K Smits, J van der Zwet, R C Buijsman, G J R Zaman, R Pieters, J P P Meijerink. Leukemia 2016
63
10

RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Valentina Gianfelici, Sabina Chiaretti, Sofie Demeyer, Filomena Di Giacomo, Monica Messina, Roberta La Starza, Nadia Peragine, Francesca Paoloni, Ellen Geerdens, Valentina Pierini,[...]. Haematologica 2016
31
10

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Daniela Bressanin, Camilla Evangelisti, Francesca Ricci, Giovanna Tabellini, Francesca Chiarini, Pier Luigi Tazzari, Fraia Melchionda, Francesca Buontempo, Pasqualepaolo Pagliaro, Andrea Pession,[...]. Oncotarget 2012
50
10

High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
Roberta La Starza, Monica Messina, Valentina Gianfelici, Valentina Pierini, Caterina Matteucci, Tiziana Pierini, Maria Zaira Limongi, Antonella Vitale, Giovanni Roti, Sabina Chiaretti,[...]. Leukemia 2018
13
23

T-cell acute lymphoblastic leukemia.
Elizabeth A Raetz, David T Teachey. Hematology Am Soc Hematol Educ Program 2016
100
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.